pSivida launches social media push

pSivida (ASX:PVA) has announced a social media push to help it better connect with shareholders and other interested parties.

The drug delivery company has launched official channels on each of the most popular social networks - Twitter, Facebook, LinkedIn and Google+.

The company will use the channels as outlets for the communication of important information to shareholders, to complement the existing investor relations section of its website.

pSivida CEO Dr Paul Ashton will also start contributing blog posts to The Chairman’s Blog, an online outlet for public and private companies to share insights about their company and industry.

“pSivida has always believed it is important to provide communication with shareholders and others,” Ashton said. “These new online channels will provide us another method to reach them.”

The US-headquartered, ASX-listed pSivida develops sustained-release drug delivery products for eye disease treatments.

Marketing partner Alimera recently refiled an FDA submission seeking approval for Iluvien, which uses a pSivida insert, in the US. Iluvien is already approved in several European markets.

pSivida has independently secured FDA approval for two other implant products: Retisert and Vitrasert.

pSivida shares were trading unchanged at $2.10 as of around 12.30 pm on Thursday.